X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (160) 160
index medicus (119) 119
humans (111) 111
colorectal cancer (89) 89
colorectal neoplasms - drug therapy (76) 76
female (76) 76
male (75) 75
aged (63) 63
chemotherapy (59) 59
middle aged (58) 58
colorectal neoplasms - pathology (57) 57
bevacizumab (54) 54
cancer (49) 49
metastasis (47) 47
adult (45) 45
colorectal neoplasms - genetics (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (44) 44
cetuximab (36) 36
prognosis (35) 35
camptothecin - analogs & derivatives (32) 32
research (31) 31
neoplasm metastasis (28) 28
care and treatment (27) 27
metastases (27) 27
treatment outcome (27) 27
colorectal carcinoma (26) 26
colorectal neoplasms - mortality (26) 26
disease-free survival (25) 25
survival (25) 25
metastatic colorectal cancer (24) 24
aged, 80 and over (23) 23
tumors (23) 23
antineoplastic agents - therapeutic use (21) 21
camptothecin - administration & dosage (21) 21
genetic aspects (21) 21
oxaliplatin (21) 21
retrospective studies (21) 21
fluorouracil - administration & dosage (20) 20
irinotecan (20) 20
patients (20) 20
mutation (19) 19
biomarkers (18) 18
drug therapy (18) 18
angiogenesis (17) 17
fluorouracil (17) 17
panitumumab (17) 17
ras proteins - genetics (17) 17
analysis (16) 16
angiogenesis inhibitors - therapeutic use (16) 16
antibodies, monoclonal, humanized (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (16) 16
clinical trials (16) 16
expression (16) 16
receptor, epidermal growth factor - antagonists & inhibitors (16) 16
1st-line treatment (15) 15
leucovorin (15) 15
leucovorin - administration & dosage (15) 15
proto-oncogene proteins p21 (15) 15
antibodies, monoclonal - therapeutic use (14) 14
metastatic colorectal-cancer (14) 14
polymorphism, single nucleotide (14) 14
proto-oncogene proteins - genetics (14) 14
survival analysis (14) 14
antibodies, monoclonal - administration & dosage (13) 13
hematology, oncology and palliative medicine (13) 13
kaplan-meier estimate (13) 13
kras (13) 13
liver metastases (13) 13
monoclonal antibodies (13) 13
organoplatinum compounds - administration & dosage (13) 13
pharmacology & pharmacy (13) 13
single-nucleotide polymorphism (13) 13
therapy (13) 13
usage (13) 13
article (12) 12
braf (12) 12
health aspects (12) 12
5-fluorouracil (11) 11
bevacizumab - therapeutic use (11) 11
digestive system diseases (11) 11
infusional fluorouracil (11) 11
liver neoplasms - secondary (11) 11
proto-oncogene proteins b-raf - genetics (11) 11
vascular endothelial growth factor (11) 11
1st-line therapy (10) 10
camptothecin - therapeutic use (10) 10
cancer patients (10) 10
cancer therapies (10) 10
capecitabine (10) 10
cells (10) 10
fluorouracil - therapeutic use (10) 10
genotype (10) 10
liver neoplasms - drug therapy (10) 10
medicine & public health (10) 10
medicine, research & experimental (10) 10
mutations (10) 10
phase-iii (10) 10
resistance (10) 10
trial (10) 10
abridged index medicus (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
In patients with metastatic colon cancer, fluorouracil, oxaliplatin, and irinotecan plus bevacizumab, as compared with fluorouracil and irinotecan plus... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INFUSIONAL FLUOROURACIL | LEUCOVORIN | MANAGEMENT | PHASE-III | GUIDELINES | IRINOTECAN | OXALIPLATIN | CHEMOTHERAPY | FOLFIRI | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 09/2017, Volume 18, Issue 9, pp. 1139 - 1141
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Summary Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil,... 
Hematology, Oncology and Palliative Medicine | LIVER METASTASES | INFUSIONAL FLUOROURACIL | LEUCOVORIN | K-RAS | PLUS IRINOTECAN | ONCOLOGY | CLINICAL-TRIALS | TUMOR RESPONSE | ORAL FLUOROPYRIMIDINES | BICC-C | CHEMOTHERAPY | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Organoplatinum Compounds - adverse effects | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Angiogenesis inhibitors | Drug therapy | Cancer | Medical research | Analysis | Medicine, Experimental | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 16, pp. 2622 - 2629
Purpose PTEN, AKT, and KRAS are epidermal growth factor receptor (EGFR) downstream regulators. KRAS mutations confer resistance to cetuximab. This... 
CELL LUNG-CANCER | PANITUMUMAB | K-RAS MUTATIONS | THERAPY | GROWTH-FACTOR-RECEPTOR | EFFICACY | ONCOLOGY | SIGNALING PATHWAY | RESISTANCE | EGFR | CHEMOTHERAPY | Immunohistochemistry | Predictive Value of Tests | ras Proteins - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | PTEN Phosphohydrolase - analysis | Drug Resistance, Neoplasm | Male | Patient Selection | Antibodies, Monoclonal, Humanized | Antineoplastic Agents, Phytogenic - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Cetuximab | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Colorectal Neoplasms - enzymology | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Colorectal Neoplasms - secondary | Italy - epidemiology | Aged | Mutation | Longitudinal Studies | Index Medicus
Journal Article
BioMed research international, ISSN 2314-6133, 01/2018, Volume 2018, pp. 5184075 - 2
Cancer cells may decrease the expression of tumor antigens on their surface, making it harder for the immune system to detect them, express on their surface... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | Immune response | Immunotherapy | Biomarkers | T cell receptors | Bioindicators | Lymphocytes T | FDA approval | Cancer therapies | Cancer | Immune system | Tumors | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
Modern Pathology, ISSN 0893-3952, 11/2015, Volume 28, Issue 11, pp. 1481 - 1491
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2013, Volume 133, Issue 1, pp. 43 - 57
Journal Article
British Journal of Cancer, ISSN 0007-0920, 12/2018, Volume 119, Issue 12, pp. 1451 - 1455
BACKGROUND: Two first-line (1L) bevacizumab trials showed the prognostic value of primary tumour location in metastatic colorectal cancer (mCRC). In this... 
SURVIVAL | SITE | SIDED COLON-CANCER | ONCOLOGY | Chemotherapy | Colorectal carcinoma | Colorectal cancer | Clinical trials | Metastasis | Survival | Patients | Subgroups | Tumors | Cancer | Bevacizumab | Metastases | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2007, Volume 25, Issue 10, pp. 1247 - 1254
Journal Article